Compare · DXCM vs PRCT
DXCM vs PRCT
Side-by-side comparison of DexCom Inc. (DXCM) and PROCEPT BioRobotics Corporation (PRCT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and PRCT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.65B, about 27.2x PRCT ($1.24B).
- PRCT has been more active in the news (11 items in the past 4 weeks vs 9 for DXCM).
- Both have 25 recent analyst ratings on file.
- Company
- DexCom Inc.
- PROCEPT BioRobotics Corporation
- Price
- -
- -
- Market cap
- $33.65B
- $1.24B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2021
- News (4w)
- 9
- 11
- Recent ratings
- 25
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 101,502 units (SEC Form 4) (withholding obligation)
- EVP, Chief Financal Officer Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.96% to 150,390 units (SEC Form 4) (withholding tax)
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 418,908 units (SEC Form 4) to satisfy withholding tax
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 128,608 units (SEC Form 4) (withholding tax)
- Executive Chair Sayer Kevin R sold $2,408,242 worth of shares (26,756 units at $90.01) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 302,214 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $156,281 worth of shares (1,700 units at $91.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 102,953 units (SEC Form 4)
- Director Augustinos Nicholas gifted 1,075 shares (SEC Form 4)
- Director Heller Bridgette P sold $89,349 worth of shares (1,012 units at $88.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 29,570 units (SEC Form 4)
- Director Foletta Mark G sold $330,640 worth of shares (4,000 units at $82.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by DexCom Inc.
Latest PRCT
- PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026
- EVP, Chief Technology Officer Templin Barry L was granted 26,246 shares, increasing direct ownership by 38% to 95,199 units (SEC Form 4)
- EVP, CLO, CORP. SEC. Nouri Alaleh was granted 22,965 shares, increasing direct ownership by 22% to 128,034 units (SEC Form 4)
- EVP, CFO Waters Kevin was granted 29,527 shares, increasing direct ownership by 20% to 180,728 units (SEC Form 4)
- Chief Strat/Marketing Officer Sharma Pooja was granted 23,622 shares, increasing direct ownership by 27% to 111,181 units (SEC Form 4)
- President, CEO Wood Larry L bought $498,315 worth of shares (23,900 units at $20.85) (SEC Form 4)
- SEC Form 10-Q filed by PROCEPT BioRobotics Corporation
- PROCEPT BioRobotics downgraded by William Blair
- PROCEPT BioRobotics downgraded by Wells Fargo with a new price target
- PROCEPT BioRobotics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits